Compare funds
Pick up to 10 funds. Compare funds from the same category for a fair reading.
Growth of ₹10,000
Basics
| HDFC Pharma and Healthcare Fund | Baroda BNP Paribas ESG Best-in-Class Strategy Fund | |
|---|---|---|
| Category | Sectoral / Thematic | Sectoral / Thematic |
| Plan | Direct | Direct |
| Fund house | HDFC | Baroda BNP |
| NAV | ₹23.6750 | ₹10.9097 |
| NAV date | 20 Nov 2026 | 20 Nov 2026 |
| History | 3.1 years | 9 months |
| Expense ratio | 1.1% | 1.2% |
| Stars | ★★★★★ | Not rated |
| Growth Score | 94.50 | — |
Returns
| HDFC Pharma and Healthcare Fund | Baroda BNP Paribas ESG Best-in-Class Strategy Fund | |
|---|---|---|
| 1 month | +12.97% | +9.70% |
| 3 months | +7.13% | +1.66% |
| 6 months | +17.84% | +6.67% |
| YTD | +33.73% | — |
| 1 year | +32.20% | — |
| 3 years (CAGR) | +30.70% | — |
| 5 years (CAGR) | — | — |
| 10 years (CAGR) | — | — |
| Since launch | +31.83% | +8.90% |
Risk
| HDFC Pharma and Healthcare Fund | Baroda BNP Paribas ESG Best-in-Class Strategy Fund | |
|---|---|---|
| Volatility | 15.8% | — |
| Downside volatility | 8.5% | — |
| Sharpe | 1.53 | — |
| Sortino | 2.86 | — |
| Calmar | 2.06 | — |
| Return / risk | 1.95 | — |
| Deepest fall | −14.91% | −10.15% |
| Days to recover | 126 | 43 |
| Below its high | +0.00% | +0.00% |
Against benchmark
| HDFC Pharma and Healthcare Fund | Baroda BNP Paribas ESG Best-in-Class Strategy Fund | |
|---|---|---|
| Alpha | +7.54% | — |
| Beta | 0.97 | — |
| R² | 85.0% | — |
| Up capture | 108.9% | — |
| Down capture | 71.0% | — |
| Tracking error | 6.1% | — |
| Information ratio | 1.17 | — |
| Treynor | 0.24 | — |
Consistency
| HDFC Pharma and Healthcare Fund | Baroda BNP Paribas ESG Best-in-Class Strategy Fund | |
|---|---|---|
| Best 1-year | +67.01% | — |
| Middle 1-year | +23.25% | — |
| Worst 1-year | +1.71% | — |
| 1-year periods with a loss | 0.0% | — |
| Middle 3-year | +30.22% | — |
| Positive months | 72.2% | — |
| Best day | +3.18% | +2.40% |
| Worst day | −3.61% | −1.90% |
| Worst 5% day | −1.51% | −1.11% |
| Positive days | 58.3% | 54.3% |
| NAVs a year | 247 | 176 |
SIP of ₹10,000 a month
| HDFC Pharma and Healthcare Fund | Baroda BNP Paribas ESG Best-in-Class Strategy Fund | |
|---|---|---|
| 5-year XIRR | — | — |
| 5-year value | — | — |
| 3-year XIRR | +27.71% | — |
| 1-year XIRR | +41.37% | — |
Holdings overlap i
Overlap needs the monthly portfolio filing of at least two of these funds; not loaded yet.